Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.52 ▲ +0.19
(+5.71%)
MKT CAP: $11.3M • VOL: 16.7K
52W L $3 52W H $20
ROARABLE / RQD
D • 51/100
PIOTROSKI
3 / 9
PASG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$49.3M | -$70.4M | -$108.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$45.5M | -$64.8M | -$102.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$31.5M | -$48.0M | -$78.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$31.5M | -$48.0M | -$78.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $46.3M | $37.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $18.8M | $61.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PASG.